PD-L1

[Nature Communications] Scientists demonstrated a previously undescribed tumor cell-intrinsic role for glucocorticoid receptor (GR) in activating PD-L1 expression and repressing the major histocompatibility complex class I expression in pancreatic ductal adenocarcinoma cells through transcriptional regulation.

[npj Breast Cancer] The authors discuss the biological understanding of tumor-infiltrating lymphocytes (TILs), their analytical and clinical validity and efforts towards the clinical utility in breast cancer, and the current status of programmed death-ligand 1and TIL testing across different continents.

[Cancer Immunology Research] An epigenetic CRISPR-Cas9 screen of 1,218 chromatin regulators identified TRIM28 as a suppressor of PD-L1 expression.

[Clinical Cancer Research] Researchers proved that anlotinib facilitated tumor vessel normalization at least partially through CD4+ T cells, reprogrammed the immunosuppressive tumor microenvironment (TME) into an immunostimulatory TME, significantly inhibited tumor growth and effectively prevented systemic immunosuppression.

[ACS Nano] Investigators described a strategy that utilizes pretargeting and glycochemistry to bioengineer β cells in situ to induce β-cell-specific tolerance.

[Life Sciences] Scientists inhibited two of the most important immune checkpoints expressed on T cells infiltrated in tumors, including PD-1 and A2aR. Ligation of PD-1 with PD-L1 and A2aR with adenosine significantly suppress T cell responses against tumor cells.